Fabrication of a hyaluronic acid conjugated metal organic framework for targeted drug delivery and magnetic resonance imaging
Since metal organic frameworks (MOF) have exhibited fascinating potential in biomedical applications, it is worthwhile to construct a MOF-based multifunctional drug delivery system. In the present study, the anticancer drug doxorubicin (DOX) was loaded into zeolitic imidazolate framework-8 (ZIF-8) v...
Gespeichert in:
Veröffentlicht in: | RSC advances 2018-01, Vol.8 (12), p.6581-6589 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Since metal organic frameworks (MOF) have exhibited fascinating potential in biomedical applications, it is worthwhile to construct a MOF-based multifunctional drug delivery system. In the present study, the anticancer drug doxorubicin (DOX) was loaded into zeolitic imidazolate framework-8 (ZIF-8)
via
a one-pot process. The formed DOX@ZIF-8 was then coated with polydopamine, successively chelated with Fe
3+
and conjugated with hyaluronic acid (HA), finally resulting in a multifunctional ZIF-8 nanocarrier. The characterization results confirmed the successful formation of the hybrid nanocarrier. pH-responsive drug release of DOX was observed due to the innate pH-dependent stability of ZIF-8. Importantly, the flow cytometry and confocal laser scanning microscope results both verified the targeting ability of DOX@ZIF-HA toward prostate cancer PC-3 cells. The improved therapeutic efficacy of DOX@ZIF-HA when compared to the inhibited group was also demonstrated. Furthermore, the chelation of Fe
3+
by PDA makes the prepared DOX@ZIF-HA a good contrast agent for magnetic resonance (MR) imaging. Hence, we hope the constructed ZIF-8 based multifunctional nanocarrier could be a candidate for cancer theranostics.
DOX-doped MOF nanoparticles were prepared
via
a one-pot reaction and successively anchored with Fe
3+
and HA for simultaneous targeted drug delivery and MR imaging. |
---|---|
ISSN: | 2046-2069 2046-2069 |
DOI: | 10.1039/c7ra12969f |